A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Ciuleanu, T. E.
Kurteva, G.
Ocvirk, J.
Beslija, S.
Koza, I.
Papamichael, D.
Vrbanec, D.
Brodowicz, T.
Scheithauer, W.
Zielinski, C. C.
机构：
[1] Inst Oncol Cluj, Cluj Napoca, Romania
[2] Sbalo Natl Oncol Ctr, Sofia, Bulgaria
[3] Inst Oncol, Ljubljana, Slovenia
[4] Inst Oncol, Sarajevo, Bosnia & Herceg
[5] Natl Canc Inst, Bratislava, Slovakia
[6] Banc Cyprus Oncol Ctr, Nicosia, Cyprus
[7] Univ Hosp Rebro, Zagreb, Croatia
[8] Med Univ Vienna, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4032
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.
    Garcia-Carbonero, Rocio
    Rivera, Fernando
    Maurel, Juan
    Ayoub, Jean-Pierre M.
    Moore, Malcolm J.
    Cervantes-Ruiperez, Andres
    Asmis, Timothy R.
    Schwartz, Jonathan D.
    Ballal, Shaila
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [32] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    De Braud, F. G.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [34] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
    Zhou, Fuxiang
    Wang Wen-bo
    Xia, Ling
    Dai, Jing
    Wu, Han
    Yang, Lei
    Xiong, Zhiguo
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
  • [35] Efficacy and safety of FOLFOX biweekly cetuximab as first-line therapy for patients with nonresectable metastatic colorectal cancer (CELINE trial): Multicenter phase II trial.
    Kondo, Ken
    Kotake, Masanori
    Doden, Kenji
    Munemoto, Yoshinori
    Kobayashi, Kenji
    Nishimura, Genichi
    Omote, Kazuhiko
    Sakamoto, Junichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [36] A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer
    Hickish, Tamas
    Cassidy, Jim
    Propper, David
    Chau, Ian
    Falk, Stephen
    Ford, Hugo
    Iveson, Tim
    Braun, Michael
    Potter, Vanessa
    Macpherson, Iain R.
    Finnigan, Helen
    Lee, Chooi
    Jones, Hilary
    Harrison, Mark
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3136 - 3144
  • [37] A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results
    Maroun, Jean Alfred
    Jonker, Derek J.
    Cripps, M. Christine
    Asmis, Timothy R.
    Goel, Rakesh
    Goodwin, Rachel Anne
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
    Folprecht, G.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Zubel, A.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
    Qin, Shukui
    Li, Jin
    Wang, Liwei
    Xu, Jianming
    Cheng, Ying
    Bai, Yuxian
    Li, Wei
    Xu, Nong
    Lin, Li-zhu
    Wu, Qiong
    Li, Yunfeng
    Yang, Jianwei
    Pan, Hongming
    Ouyang, Xuenong
    Qiu, Wensheng
    Wu, Kaichun
    Xiong, Jianping
    Dai, Guanghai
    Liang, Houjie
    Hu, Chunhong
    Zhang, Jun
    Tao, Min
    Yao, Qiang
    Wang, Junyuan
    Chen, Jiongjie
    Eggleton, S. Peter
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) : 3031 - +
  • [40] Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).
    Moosmann, N.
    von Weikersthal, L. Fischer
    Vehling-Kaiser, U.
    Stauch, M.
    Dietzfelbinger, H. F.
    Oruzio, D. V.
    Klein, S.
    Stintzing, S.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345